ROSAI DORFMAN DISEASE
Clinical trials for ROSAI DORFMAN DISEASE explained in plain language.
Never miss a new study
Get alerted when new ROSAI DORFMAN DISEASE trials appear
Sign up with your email to follow new studies for ROSAI DORFMAN DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets rare immune diseases that resist standard care
Disease control Recruiting nowThis study tests a drug called cobimetinib in children and adults with histiocytic disorders that have come back or not responded to other treatments. Cobimetinib blocks a faulty growth signal inside cells. The goal is to see if the drug can shrink tumors and slow the disease. Ab…
Matched conditions: ROSAI DORFMAN DISEASE
Phase: PHASE2 • Sponsor: Carl Allen • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug cocktail aims to tame rare immune disease
Disease control Recruiting nowThis study tests whether a combination of lenalidomide and dexamethasone can control Rosai-Dorfman disease, a rare disorder where immune cells build up and cause lumps. About 40 adults aged 18 to 80 who are newly diagnosed or have not responded to prior treatment will receive the…
Matched conditions: ROSAI DORFMAN DISEASE
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New PET tracer could reveal hidden cancer spots
Knowledge-focused Recruiting nowThis early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood cancers and solid tumors on PET/CT scans. About 30 people with conditions like multiple myeloma, non-Hodgkin lymphoma, or histiocytic neoplasms will receive t…
Matched conditions: ROSAI DORFMAN DISEASE
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 13, 2026 15:59 UTC